ClinicalTrials.gg
TerminatedNCT03615924HESTIA3Updated Apr 9, 2021Results posted

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

A Phase 3 interventional study of Ticagrelor and Placebo in Sickle Cell Disease, sponsored by AstraZeneca. Terminated at 55 sites in 16 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-04-09.

Primary conditionVaso-Occlusive CrisesRegistry: Anemia, Sickle CellReclassifiedWhy we changed it
Registry
Anemia, Sickle Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Vaso-Occlusive Crises
Why
  1. The study's title name Vaso-Occlusive Crises, a narrower term within Anemia, Sickle Cell.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
Recommendation from an independent data monitoring committee (DMC) and accepted by AstraZeneca.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Enrollment
10th of 56
193 · median 63
Started
2018
with 3 others
Phase 3
17 of 60
3 open now
Registered
32nd of 60
by date

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 10th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2018, is one of 17 in phase 3, and was the 32nd registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease

Read the detailed description

Hestia3 will evaluate the efficacy, safety and tolerability of ticagrelor versus placebo in children with SCD during treatment for at least 12 months and up to approximately 24 months.

  • The target population are children aged ≥2 to \<18 years of age and body weight of ≥12 kg diagnosed with HbSS or HbS/β0 confirmed by high-performance liquid chromatography or hemoglobin electrophoresis. At least 50 evaluable patients should be recruited in each of the age groups, ≥2 years to \<12 years and ≥12 years to \<18 years.
  • To be eligible for the study, patients must have experienced at least 2 VOCs (defined as painful crisis and/or ACS) events in the past 12 months prior to Visit 1, indicating that the severity of the patient's disease justifies preventive chronic long-term treatment. The intent is to enroll only children aged 2 years or above, since VOCs become more frequent with age.
  • Study participants should receive standard of care for SCD, adjusted to the individual patient at the discretion of the investigator, including routine health care screening examinations and immunizations according to local guidelines and health care programmers. Study drug will be given on the background of standard treatments for SCD. Study participants are not withheld from any other treatments that may be used in SCD (eg., hydroxyurea) during the trial, which is important considering the use of a placebo control group. However, restrictions apply to some medications and interventions that may be necessary for the patient's health and well-being during the study.
  • Patients are to be followed up to 24 months or until a common study end date is reached defined as 12 months after the last patient is randomised. The expected average follow-up is 18 months. Considering inclusion of patients with at least 2 VOC events in the past year, this treatment duration is considered long enough to evaluate effects on VOC events as well as to capture safety and tolerability data supporting a potential future long term use of ticagrelor.
  • Due to ticagrelor mechanism of action and the potential to reduce symptoms caused by ischemia during a vaso-occlusion, a composite endpoint with painful crises and/or ACS has been selected for the primary endpoint. Painful crisis is the most common reason for emergency department visits for patients with SCD with a significant impact on young patients' lives, affecting them physically and emotionally. Secondary endpoints are included to broaden the understanding of effects in patients with SCD and to also assess potential benefits on symptomatic disease burden and health-related quality of life (HRQL).
  • Patients will be treated with 15, 30 and 45 mg bd or matching placebo, depending on body weight.
03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Sickle Cell Disease
  • Sickle Cell Anemia
  • SCD
  • Platelet aggregation
  • Ticagrelor
  • Brilinta
  • VOC
  • Vaso-Occlusive Crises
  • ACS
  • painful crisis
04

In context

Vaso-Occlusive Crises Reclassified

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

This study's enrollment of 193 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.

Browse Vaso-Occlusive Crises studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated prior to any study specific procedures not part of standard medical care (local regulations and international guidelines are to be followed in determining the assent/consent requirements for children).
  2. Male or female paediatric patients aged ≥2 to \<18 years and body weight of ≥12 kg (at Visit 1), diagnosed with HbSS or HbS/β0 as confirmed by high-performance liquid chromatography or electrophoresis.

    Note: Diagnosis of SCD (if not confirmed prior to screening and records available on the medical file) should be confirmed for HbSS or HbS/β0 by high-performance liquid chromatography or haemoglobin electrophoresis, performed at the site's local lab, in order to confirm the type of mutation.

  3. Have experienced at least 2 VOCs (painful crisis and/or ACS) as judged by the Investigator in the past 12 months prior to Visit 1. These VOCs need to be documented in the patient's medical records or in other documents that can be reconciled.
  4. If ≤16 years old, must have had transcranial Doppler (TCD) within the past year prior to Visit 1. If this is not the case, a TCD examination must be done before proceeding in the study.
  5. If ≥10 years old, must have had an ophthalmological examination within the past year prior to Visit 1. If this is not the case, the patient must be examined by an ophthalmologist before proceeding in the study. If local guidelines dictate ophthalmological examination at younger ages, those local guidelines should be followed.
  6. If treated with hydroxyurea, the weight-adjusted dose must be stable for 3 months before screening.
  7. Suitable venous access for the study-related blood sampling
  8. Prior to dosing on day of randomisation (Visit 2), a negative urine (dipstick) pregnancy test performed at Screening (Visit 1) and at Visit 2 must be available for female patients of .
  9. Females of childbearing potential (after menarche) must not become pregnant during study. Sexually active females must use a highly effective method of which results in a low failure rate (ie, less than 1% per year). If use of effective contraception cannot be secured in sexually active females, the patient cannot be included in this study.

Exclusion criteria

Exclusion Criteria:

  1. History of (TIA) or cerebrovascular accident (ischaemic or haemorrhagic), severe head trauma, intracranial haemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or proliferative retinopathy.
  2. Findings on TCD: Current or previous values for time averaged mean of the maximum velocity (TAMMV) that are Conditional or Abnormal. Patients with Conditional TAMMV values or higher (≥153 cm/sec using TCD imaging technique [TCDi] which is corresponding to ≥170 cm/sec by the non-imaging technique). Both the middle cerebral artery and the internal carotid artery should be considered.

    Any other criteria that would locally be considered as TCD indications for chronic transfusion would also exclude the patient.

  3. Active pathological bleeding or increased risk of bleeding complications according to Investigator
  4. \<6 g/dL from test performed at Screening (Visit 1)
  5. \<100 x 10\^9/L from test performed at Screening (Visit 1) Undergoing treatment with chronic red blood cell transfusion therapy.
  6. Undergoing treatment with chronic red blood cell transfusion therapy.
  7. Chronic use of NSAIDs defined as continuous intake >3 days per week that cannot be discontinued
  8. Receiving chronic treatment with anticoagulants or antiplatelet drugs that cannot be discontinued
  9. Moderate or severe hepatic impairment defined as laboratory values of (ALT) >2 × (ULN), total >2 × ULN (unless judged by the Investigator to be caused by haemolysis), albumin \<35 g/L (3.5 g/dL) and (INR) >1.4, or symptoms of liver disease (eg, ascites) from test performed at Screening (Visit 1).
  10. Renal failure requiring dialysis
  11. Patient considered to be at risk of bradycardic events (eg, known sick sinus syndrome or second or third degree atrioventricular block) unless already treated with a permanent pacemaker.
  12. Concomitant oral or intravenous therapy with strong or moderate cytochrome P450 3A () inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers, which cannot be stopped at least 5 half-lives before randomisation.
  13. Active untreated malaria. Patients with suspected malaria at Screening (Visit 1) will be tested.
  14. Known or to ticagrelor
  15. Patients who are currently pregnant or breastfeeding, or planning to become pregnant during the study or have given birth less than 3 months prior to Screening (Visit 1)
  16. Any condition which, in the opinion of the Investigator, would make it unsafe or unsuitable for the patient to participate in this study
  17. Concern for the inability of the patient or caregiver (defined as legally authorized representative) to comply with study procedures and/or follow-up
  18. Previous randomisation in the present study.
  19. Participation in another clinical study with an IP or device during the last 30 days preceding screening.
  20. Involvement of member of patient's family, or patient self, in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day * \>48 kg: Ticagrelor 45 mg, twice a day.

    Drug: Ticagrelor

  • Placebo comparator
    Placebo

    The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day * \>48 kg: Placebo to match ticagrelor 45 mg, twice a day.

    Drug: Placebo

Interventions

  • The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day * \>48 kg: Ticagrelor 45 mg, twice a day.

  • DrugPlacebo

    The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day * \>48 kg: Placebo to match ticagrelor 45 mg, twice a day.

07

What researchers measure

Primary outcomes

  1. Number of Vaso-Occlusive Crisis Events

    A VOC is the composite of a painful crisis and/or an acute chest syndrome (ACS) event. The number of VOC events is defined as the count of VOC events experienced by a participant throughout the treatment period.

    Time frame: From randomization (Day 0) up to end of study (EOS) visit or date of premature study discontinuation, up to approximately 20 months

Secondary outcomes

  1. Number of Painful Crisis Events

    A painful crisis is an onset or worsening of pain that lasts at least 2 hours, for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, parenteral non-steroidal anti-inflammatory drugs, or other analgesics prescribed by a healthcare provider in a medical setting (such as a hospital, clinic or emergency room visit) or at home. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  2. Number of Acute Chest Syndrome Events

    The ACS is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  3. Duration of Painful Crises

    The duration of painful crises is defined as the sum of the duration of painful crises experienced by a participant over the defined treatment period. If two or more events have overlapping durations, the overlapping days were counted only once.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  4. Number of Vaso-Occlusive Crisis Events Requiring Hospitalization or Emergency Department Visits

    The number of VOC events requiring hospitalization or emergency department visits is defined as the count of VOC events experienced by a participant over the treatment period, for which the primary setting for VOC treatment was in-patient hospitalization or emergency department. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  5. Number of Days Hospitalized for Vaso-Occlusive Crisis Events

    The number of days hospitalized for all individual VOC events experienced by a participant during the treatment period is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days of VOC components) during VOC events experienced by a participant over the treatment period for which the primary setting for VOC treatment was in-patient hospitalization.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  6. Number of Acute Sickle Cell Disease Complications

    The number of acute SCD complications is defined as the count of all individual acute SCD complications experienced by a participant over the treatment period. Acute SCD complications are defined as any one or more of the following individual complications: Transient ischaemic attack/ischaemic stroke, hepatic sequestration, splenic sequestration, priapism, and dactylitis.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  7. Number of Days Hospitalized for Acute Sickle Cell Disease Complications

    The number of days hospitalized for acute SCD complications is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days) due to acute SCD complications experienced by a participant over the treatment period, for which hospitalization was reported.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  8. Number of Sickle Cell-Related Red Blood Cell (RBC) Transfusions

    The number of participants with at least one sickle cell-related RBC transfusion reported. Adverse events resulting in the need for RBC transfusions were captured prior to database lock to determine if the transfusion was sickle cell-related or not.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  9. Health-Related Quality of Life Total Score Using the Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module

    The PedsQL SCD module instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL SCD module measures problems in the following categories: * Pain: 3 sub-scales * Worry: 2 sub-scales * Emotions: 1 sub-scale * Treatment: 1 sub-scale * Communication: 2 sub-scales * Total score PedsQL SCD module items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL SCD module total score (43/42/40 items - depending on version completed) the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are the closest observation prior to and including the randomization visit.

    Time frame: For ages ≥2 to <5 years and ≥5 to <8 years: Baseline (observation prior to and including the randomization visit) and Months 6, and 12; For ages ≥8 to <13 years and ≥13 to ≤18 years: Baseline and Months 6, 12, and 18

  10. Fatigue Total Score Using Pediatric Quality of Life Inventory Multidimensional Fatigue Scale

    The PedsQL multidimensional fatigue scale instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL multidimensional fatigue scale measures problems in the following categories: * General (6 items) * Sleep/rest (6 items) * Cognitive fatigue (6 items) * Total score (18 items) PedsQL multidimensional fatigue scale items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL multidimensional fatigue scale total score (18 items), the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are closest observation prior to and including randomization visit.

    Time frame: For ages ≥2 to <5 years and ≥5 to <8 years: Baseline (observation prior to and including the randomization visit) and Months 6, and 12; For ages ≥8 to <13 years and ≥13 to ≤18 years: Baseline and Months 6, 12, and 18

  11. Percentage of Days of Absence From School or Work Due to Sickle Cell Disease

    For participants attending school/work at randomization, absence from school/work due to SCD was recorded weekly by the participant in the eDevice with the help of the caregiver if needed. The percentage of days absent from school/work due to SCD in the defined treatment period was calculated as follows: Percentage of absent days = (total number of days reported)/(total number of questionnaires answered ×7).

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  12. Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants <5 Years of Age

    The Face, Legs, Activity, Cry, Consolability (FLACC) scale is caregiver-reported and used to assess pain daily during the VOC event for those participants \<5 years of age as determined at randomization. Each of the 5 behaviours observed are assigned a score of 0, 1 or 2. The total FLACC score ranges between 0 and 10, with 0 representing "no pain" and 10 representing "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  13. Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants ≥5 Years of Age

    The Faces Pain Scale-revised (FPS-R) was administered to assess pain daily during the VOC event by those participants aged ≥5 years as determined at randomization. The FPS-R consists of 6 faces and scoring ranges between 0 and 10 (with an increase in numeric value by 2), where 0 is "no pain" and 10 is "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  14. Type of Analgesics Used by Participants During Vaso-Occlusive Crisis Events

    Analgesics use (opioid and non-opioid) during VOC events.

    Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months

  15. Palatability of the Study Treatment Assessed by Study Medication Palatability Assessment (SMPA) in Participants ≤4 Years of Age

    Response to palatability was assessed through the SMPA question "Was any behaviour observed when the study medication was given to this participant that would be indicative of a negative response to the palatability of the study medication?". This was presented as a binary outcome (that is, where "No" is no negative response and "Yes" is negative response). No negative response was considered as a positive outcome.

    Time frame: Baseline (randomization visit) and Month 6

  16. Swallowability of the Study Treatment Assessed by Study Medication Palatability Assessment in Participants ≤4 Years of Age

    An observer's assessment of the participant's behaviour using the SMPA was performed for all participants taking the study treatment who are 2 to 4 years of age. Willingness to swallow was assessed and categorized as follows: * Swallowed without a problem * Some resistance but did swallow * Spit out some/all of the medication * Vomited up the medication. The category "swallowed without a problem" was considered as positive outcome.

    Time frame: Baseline (randomization visit) and Month 6

  17. Palatability of the Study Treatment Assessed by Facial Hedonic Scale (FHS) in Participants ≥5 Years of Age

    The FHS method was used for all participants taking the study treatment who are ≥5 years of age. The FHS consists of 5 faces with descriptions ranging from "Dislike very much" to "Like very much". The face with description "Like very much" was considered as positive outcome. The way in which the study treatment was taken, that is, whether the tablet is whole or dispersed, was captured.

    Time frame: Baseline (randomization visit) and Month 6

08

Results

Posted Apr 9, 2021
Limitations and caveats
AstraZeneca took the decision to terminate the study early, following a recommendation from the independent Data Monitoring Committee. This early termination was not considered to have had an impact on the robustness of the study results.

Participant flow

This Phase III study was conducted in pediatric participants with sickle cell disease (SCD) at 53 sites in 16 countries (Kenya, India, Uganda, Egypt, Lebanon, Ghana, South Africa, Tanzania, United Kingdom, Turkey, Spain, Italy, Belgium, Greece, Brazil and United States) between 26 September 2018 and 13 August 2020.

Participant flow — Overall Study
MilestoneTicagrelor 15/30/45 mg bdPlacebo
Started10192
Received treatment10192
Completed00
Not completed10192
Withdrew: Withdrawal by subject25
Withdrew: Death31
Withdrew: Lost to follow-up10
Withdrew: Randomized in error10
Withdrew: Study termination by sponsor9486

Outcome measures

PrimaryNumber of Vaso-Occlusive Crisis Events

A VOC is the composite of a painful crisis and/or an acute chest syndrome (ACS) event. The number of VOC events is defined as the count of VOC events experienced by a participant throughout the treatment period.

Time frame:
From randomization (Day 0) up to end of study (EOS) visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · VOC events
Number of Vaso-Occlusive Crisis Events
VOC eventsTicagrelor 15/30/45 mg bdPlacebo
Number of Vaso-Occlusive Crisis Events249202
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.7597 · Incidence rate ratio: 1.06 · 95% CI 0.75 to 1.50
SecondaryNumber of Painful Crisis Events

A painful crisis is an onset or worsening of pain that lasts at least 2 hours, for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, parenteral non-steroidal anti-inflammatory drugs, or other analgesics prescribed by a healthcare provider in a medical setting (such as a hospital, clinic or emergency room visit) or at home. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · painful crisis events
Number of Painful Crisis Events
painful crisis eventsTicagrelor 15/30/45 mg bdPlacebo
Number of Painful Crisis Events248209
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.9037 · Incidence rate ratio: 1.02 · 95% CI 0.72 to 1.45
SecondaryNumber of Acute Chest Syndrome Events

The ACS is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · ACS events
Number of Acute Chest Syndrome Events
ACS eventsTicagrelor 15/30/45 mg bdPlacebo
Number of Acute Chest Syndrome Events66
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.7136 · Incidence rate ratio: 0.76 · 95% CI 0.17 to 3.30
SecondaryDuration of Painful Crises

The duration of painful crises is defined as the sum of the duration of painful crises experienced by a participant over the defined treatment period. If two or more events have overlapping durations, the overlapping days were counted only once.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · days
Duration of Painful Crises
daysTicagrelor 15/30/45 mg bdPlacebo
Duration of Painful Crises14761441
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.4970 · Incidence rate ratio: 0.84 · 95% CI 0.50 to 1.40
SecondaryNumber of Vaso-Occlusive Crisis Events Requiring Hospitalization or Emergency Department Visits

The number of VOC events requiring hospitalization or emergency department visits is defined as the count of VOC events experienced by a participant over the treatment period, for which the primary setting for VOC treatment was in-patient hospitalization or emergency department. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · VOC events requiring hospitalization
Number of Vaso-Occlusive Crisis Events Requiring Hospitalization or Emergency Department Visits
VOC events requiring hospitalizationTicagrelor 15/30/45 mg bdPlacebo
Number of Vaso-Occlusive Crisis Events Requiring Hospitalization or Emergency Department Visits8751
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.1636 · Incidence rate ratio: 1.43 · 95% CI 0.87 to 2.36
SecondaryNumber of Days Hospitalized for Vaso-Occlusive Crisis Events

The number of days hospitalized for all individual VOC events experienced by a participant during the treatment period is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days of VOC components) during VOC events experienced by a participant over the treatment period for which the primary setting for VOC treatment was in-patient hospitalization.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · days
Number of Days Hospitalized for Vaso-Occlusive Crisis Events
daysTicagrelor 15/30/45 mg bdPlacebo
Number of Days Hospitalized for Vaso-Occlusive Crisis Events526256
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.2011 · Incidence rate ratio: 1.68 · 95% CI 0.76 to 3.75
SecondaryNumber of Acute Sickle Cell Disease Complications

The number of acute SCD complications is defined as the count of all individual acute SCD complications experienced by a participant over the treatment period. Acute SCD complications are defined as any one or more of the following individual complications: Transient ischaemic attack/ischaemic stroke, hepatic sequestration, splenic sequestration, priapism, and dactylitis.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · acute SCD complications
Number of Acute Sickle Cell Disease Complications
acute SCD complicationsTicagrelor 15/30/45 mg bdPlacebo
Number of Acute Sickle Cell Disease Complications63
SecondaryNumber of Days Hospitalized for Acute Sickle Cell Disease Complications

The number of days hospitalized for acute SCD complications is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days) due to acute SCD complications experienced by a participant over the treatment period, for which hospitalization was reported.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · days
Number of Days Hospitalized for Acute Sickle Cell Disease Complications
daysTicagrelor 15/30/45 mg bdPlacebo
Number of Days Hospitalized for Acute Sickle Cell Disease Complications06
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.9940 · Incidence rate ratio: 0.00
SecondaryNumber of Sickle Cell-Related Red Blood Cell (RBC) Transfusions

The number of participants with at least one sickle cell-related RBC transfusion reported. Adverse events resulting in the need for RBC transfusions were captured prior to database lock to determine if the transfusion was sickle cell-related or not.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · RBC transfusions
Number of Sickle Cell-Related Red Blood Cell (RBC) Transfusions
RBC transfusionsTicagrelor 15/30/45 mg bdPlacebo
Number of Sickle Cell-Related Red Blood Cell (RBC) Transfusions3949
Statistical analysis
  • Ticagrelor 15/30/45 mg bd vs Placebo · Negative binomial model · p = 0.4822 · Incidence rate ratio: 0.77 · 95% CI 0.38 to 1.58
SecondaryHealth-Related Quality of Life Total Score Using the Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module

The PedsQL SCD module instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL SCD module measures problems in the following categories: * Pain: 3 sub-scales * Worry: 2 sub-scales * Emotions: 1 sub-scale * Treatment: 1 sub-scale * Communication: 2 sub-scales * Total score PedsQL SCD module items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL SCD module total score (43/42/40 items - depending on version completed) the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are the closest observation prior to and including the randomization visit.

Time frame:
For ages ≥2 to <5 years and ≥5 to <8 years: Baseline (observation prior to and including the randomization visit) and Months 6, and 12; For ages ≥8 to <13 years and ≥13 to ≤18 years: Baseline and Months 6, 12, and 18
Reported as:
Mean · score on a scale
Health-Related Quality of Life Total Score Using the Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module
score on a scaleTicagrelor 15/30/45 mg bdPlacebo
>=2 to <5 years: Baseline88.81 ± 14.10767.02 ± 20.041
>=2 to <5 years: Month 680.75 ± 20.77981.37 ± 14.125
>=2 to <5 years: Month 12—88.10 ± NA
>=5 to <8 years: Baseline75.05 ± 20.14774.04 ± 21.646
>=5 to <8 years: Month 683.04 ± 15.33284.91 ± 18.117
>=5 to <8 years: Month 1265.63 ± 48.61497.50 ± NA
>=8 to <13 years: Baseline62.35 ± 24.72567.98 ± 24.338
>=8 to <13 years: Month 676.52 ± 17.18975.76 ± 21.749
>=8 to <13 years: Month 1283.20 ± 13.47964.12 ± 27.253
>=8 to <13 years: Month 1886.05 ± NA—
>=13 to <=18 years: Baseline64.45 ± 18.74660.81 ± 24.979
>=13 to <=18 years: Month 668.13 ± 16.81174.42 ± 19.146
>=13 to <=18 years: Month 1263.05 ± 19.81073.26 ± 22.589
>=13 to <=18 years: Month 1865.12 ± NA—
SecondaryFatigue Total Score Using Pediatric Quality of Life Inventory Multidimensional Fatigue Scale

The PedsQL multidimensional fatigue scale instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL multidimensional fatigue scale measures problems in the following categories: * General (6 items) * Sleep/rest (6 items) * Cognitive fatigue (6 items) * Total score (18 items) PedsQL multidimensional fatigue scale items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL multidimensional fatigue scale total score (18 items), the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are closest observation prior to and including randomization visit.

Time frame:
For ages ≥2 to <5 years and ≥5 to <8 years: Baseline (observation prior to and including the randomization visit) and Months 6, and 12; For ages ≥8 to <13 years and ≥13 to ≤18 years: Baseline and Months 6, 12, and 18
Reported as:
Mean · score on a scale
Fatigue Total Score Using Pediatric Quality of Life Inventory Multidimensional Fatigue Scale
score on a scaleTicagrelor 15/30/45 mg bdPlacebo
>=2 to <5 years: Baseline88.06 ± 16.30470.56 ± 23.220
>=2 to <5 years: Month 684.44 ± 15.54181.94 ± 22.775
>=2 to <5 years: Month 12—94.44 ± NA
>=5 to <8 years: Baseline82.33 ± 11.45084.13 ± 16.139
>=5 to <8 years: Month 687.12 ± 10.55387.70 ± 16.076
>=5 to <8 years: Month 1295.83 ± 5.893100.00 ± NA
>=8 to <13 years: Baseline64.72 ± 26.77969.51 ± 25.261
>=8 to <13 years: Month 675.65 ± 18.57177.89 ± 22.283
>=8 to <13 years: Month 1281.48 ± 17.86665.87 ± 25.495
>=8 to <13 years: Month 1873.61 ± NA—
>=13 to <=18 years: Baseline68.06 ± 21.78167.17 ± 18.223
>=13 to <=18 years: Month 673.53 ± 19.13875.21 ± 14.913
>=13 to <=18 years: Month 1267.13 ± 22.55660.28 ± 23.664
>=13 to <=18 years: Month 1872.22 ± NA—
SecondaryPercentage of Days of Absence From School or Work Due to Sickle Cell Disease

For participants attending school/work at randomization, absence from school/work due to SCD was recorded weekly by the participant in the eDevice with the help of the caregiver if needed. The percentage of days absent from school/work due to SCD in the defined treatment period was calculated as follows: Percentage of absent days = (total number of days reported)/(total number of questionnaires answered ×7).

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Mean · percentage of days
Percentage of Days of Absence From School or Work Due to Sickle Cell Disease
percentage of daysTicagrelor 15/30/45 mg bdPlacebo
Percentage of Days of Absence From School or Work Due to Sickle Cell Disease5.24 ± 8.9424.24 ± 4.964
SecondaryAverage Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants <5 Years of Age

The Face, Legs, Activity, Cry, Consolability (FLACC) scale is caregiver-reported and used to assess pain daily during the VOC event for those participants \<5 years of age as determined at randomization. Each of the 5 behaviours observed are assigned a score of 0, 1 or 2. The total FLACC score ranges between 0 and 10, with 0 representing "no pain" and 10 representing "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Mean · score on a scale
Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants <5 Years of Age
score on a scaleTicagrelor 15/30/45 mg bdPlacebo
Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants <5 Years of Age3.4 ± 2.512.9 ± 1.99
SecondaryAverage Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants ≥5 Years of Age

The Faces Pain Scale-revised (FPS-R) was administered to assess pain daily during the VOC event by those participants aged ≥5 years as determined at randomization. The FPS-R consists of 6 faces and scoring ranges between 0 and 10 (with an increase in numeric value by 2), where 0 is "no pain" and 10 is "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Mean · score on a scale
Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants ≥5 Years of Age
score on a scaleTicagrelor 15/30/45 mg bdPlacebo
Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants ≥5 Years of Age4.5 ± 2.714.1 ± 2.02
SecondaryType of Analgesics Used by Participants During Vaso-Occlusive Crisis Events

Analgesics use (opioid and non-opioid) during VOC events.

Time frame:
From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Reported as:
Number · participants
Type of Analgesics Used by Participants During Vaso-Occlusive Crisis Events
participantsTicagrelor 15/30/45 mg bdPlacebo
Opioids: Yes4622
Opioids: No5750
Non-opioids: Yes6957
Non-opioids: No147
SecondaryPalatability of the Study Treatment Assessed by Study Medication Palatability Assessment (SMPA) in Participants ≤4 Years of Age

Response to palatability was assessed through the SMPA question "Was any behaviour observed when the study medication was given to this participant that would be indicative of a negative response to the palatability of the study medication?". This was presented as a binary outcome (that is, where "No" is no negative response and "Yes" is negative response). No negative response was considered as a positive outcome.

Time frame:
Baseline (randomization visit) and Month 6
Reported as:
Count of participants · Participants
Palatability of the Study Treatment Assessed by Study Medication Palatability Assessment (SMPA) in Participants ≤4 Years of Age
ParticipantsTicagrelor 15/30/45 mg bdPlacebo
Baseline: Whole tablet — Negative response to palatability - No58
Baseline: Whole tablet — Negative response to palatability - Yes00
Baseline: Dispersed tablet — Negative response to palatability - No12
Baseline: Dispersed tablet — Negative response to palatability - Yes00
Month 6: Whole tablet — Negative response to palatability - No49
Month 6: Whole tablet — Negative response to palatability - Yes00
Month 6: Dispersed tablet — Negative response to palatability - No11
Month 6: Dispersed tablet — Negative response to palatability - Yes00
SecondarySwallowability of the Study Treatment Assessed by Study Medication Palatability Assessment in Participants ≤4 Years of Age

An observer's assessment of the participant's behaviour using the SMPA was performed for all participants taking the study treatment who are 2 to 4 years of age. Willingness to swallow was assessed and categorized as follows: * Swallowed without a problem * Some resistance but did swallow * Spit out some/all of the medication * Vomited up the medication. The category "swallowed without a problem" was considered as positive outcome.

Time frame:
Baseline (randomization visit) and Month 6
Reported as:
Count of participants · Participants
Swallowability of the Study Treatment Assessed by Study Medication Palatability Assessment in Participants ≤4 Years of Age
ParticipantsTicagrelor 15/30/45 mg bdPlacebo
Baseline: Whole tablet — Swallow without problem58
Baseline: Whole tablet — Some resistance but did swallow00
Baseline: Whole tablet — Spit out some/all medication00
Baseline: Whole tablet — Vomited up medication00
Baseline: Dispersed tablet — Swallow without problem12
Baseline: Dispersed tablet — Some resistance but did swallow00
Baseline: Dispersed tablet — Spit out some/all medication00
Baseline: Dispersed tablet — Vomited up medication00
Month 6: Whole tablet — Swallow without problem49
Month 6: Whole tablet — Some resistance but did swallow00
Month 6: Whole tablet — Spit out some/all medication00
Month 6: Whole tablet — Vomited up medication00
Month 6: Dispersed tablet — Swallow without problem11
Month 6: Dispersed tablet — Some resistance but did swallow00
Month 6: Dispersed tablet — Spit out some/all medication00
Month 6: Dispersed tablet — Vomited up medication00
SecondaryPalatability of the Study Treatment Assessed by Facial Hedonic Scale (FHS) in Participants ≥5 Years of Age

The FHS method was used for all participants taking the study treatment who are ≥5 years of age. The FHS consists of 5 faces with descriptions ranging from "Dislike very much" to "Like very much". The face with description "Like very much" was considered as positive outcome. The way in which the study treatment was taken, that is, whether the tablet is whole or dispersed, was captured.

Time frame:
Baseline (randomization visit) and Month 6
Reported as:
Count of participants · Participants
Palatability of the Study Treatment Assessed by Facial Hedonic Scale (FHS) in Participants ≥5 Years of Age
ParticipantsTicagrelor 15/30/45 mg bdPlacebo
Baseline: Whole tablet — Dislike very much32
Baseline: Whole tablet — Dislike a little42
Baseline: Whole tablet — Not sure128
Baseline: Whole tablet — Like a little2523
Baseline: Whole tablet — Like very much4845
Baseline: Dispersed tablet — Dislike very much00
Baseline: Dispersed tablet — Dislike a little00
Baseline: Dispersed tablet — Not sure10
Baseline: Dispersed tablet — Like a little01
Baseline: Dispersed tablet — Like very much01
Month 6: Whole tablet — Dislike very much00
Month 6: Whole tablet — Dislike a little53
Month 6: Whole tablet — Not sure44
Month 6: Whole tablet — Like a little3020
Month 6: Whole tablet — Like very much4447
Month 6: Dispersed tablet — Dislike very much0—
Month 6: Dispersed tablet — Dislike a little0—
Month 6: Dispersed tablet — Not sure1—
Month 6: Dispersed tablet — Like a little0—
Month 6: Dispersed tablet — Like very much0—

Adverse events

Collected over From first dose of study treatment (Day 0) up to 7 days after last dose of study treatment, approximately 20 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor 15/30/45 mg bd3/100 (3%)44/100 (44%)82/100 (82%)
Placebo1/92 (1.1%)29/92 (31.5%)71/92 (77.2%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventTicagrelor 15/30/45 mg bdPlacebo
Sickle cell anaemia with crisisBlood and lymphatic system disorders39/10024/92
AnaemiaBlood and lymphatic system disorders6/1007/92
SepsisInfections and infestations6/1001/92
MalariaInfections and infestations4/1001/92
PneumoniaInfections and infestations4/1000/92
HypersplenismBlood and lymphatic system disorders0/1003/92
PyrexiaGeneral disorders2/1003/92
CellulitisInfections and infestations3/1000/92
InfluenzaInfections and infestations0/1002/92
ConstipationGastrointestinal disorders2/1000/92
Most frequent other events
Showing 10 of 19
Most frequent other events
EventTicagrelor 15/30/45 mg bdPlacebo
Sickle cell anaemia with crisisBlood and lymphatic system disorders60/10049/92
Pain in extremityMusculoskeletal and connective tissue disorders28/10023/92
Upper respiratory tract infectionInfections and infestations19/10024/92
HeadacheNervous system disorders24/10018/92
Back painMusculoskeletal and connective tissue disorders21/10012/92
CoughRespiratory, thoracic and mediastinal disorders17/1007/92
ArthralgiaMusculoskeletal and connective tissue disorders14/10014/92
Abdominal painGastrointestinal disorders15/10010/92
MalariaInfections and infestations12/1007/92
PyrexiaGeneral disorders11/10010/92

Baseline characteristics

The Full Analysis Set (FAS) included all randomized participants regardless of treatment received.

Age, Continuous
Age, Continuous(years)Ticagrelor 15/30/45 mg bdPlaceboTotal
Mean10.40 ± 4.12810.12 ± 3.79910.26 ± 3.967
Age, Customized
Age, Customized(Participants)Ticagrelor 15/30/45 mg bdPlaceboTotal
≥2 to <12 years6154115
>=12 to <18 years403878
Sex: Female, Male
Sex: Female, Male(Participants)Ticagrelor 15/30/45 mg bdPlaceboTotal
Female484391
Male5349102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor 15/30/45 mg bdPlaceboTotal
White252146
Black or African American6051111
Asian151530
Other156
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor 15/30/45 mg bdPlaceboTotal
Hispanic or Latino7512
Not Hispanic or Latino9487181
09

Study locations

55 sites
  • Research Site
    Fort Lauderdale, Florida 33316, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Oak Lawn, Illinois 60453, United States
  • Research Site
    Las Vegas, Nevada 89135, United States
  • Research Site
    Brooklyn, New York 11212, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Brussel, 1200, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Rio de Janeiro, 20211-080, Brazil
  • Research Site
    Salvador, 41253-190, Brazil
  • Research Site
    São Paulo, 01221010, Brazil
  • Research Site
    São Paulo, 08270-070, Brazil
  • Research Site
    Al Sharkeya, 44519, Egypt
  • Research Site
    Alexandria, 21131, Egypt
  • Research Site
    Cairo, 11521, Egypt
  • Research Site
    Cairo, 11566, Egypt
  • Research Site
    Cairo, 12655, Egypt
  • Research Site
    Dakahlia, 35516, Egypt
  • Research Site
    Accra, 233, Ghana
  • Research Site
    Ho, 0, Ghana
  • Research Site
    Kumasi, 1934, Ghana
  • Research Site
    Athens, 11521, Greece
  • Research Site
    Mumbai, 400053, India
  • Research Site
    Nagpur, 440003, India
  • Research Site
    Nagpur, 440012, India
  • Research Site
    Pune, 411001, India
  • Research Site
    Pune, 411004, India
  • Research Site
    Wardha, 442004, India
  • Research Site
    Catania, 95123, Italy
  • Research Site
    Naples, 80138, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Kisumu, 40100, Kenya
  • Research Site
    Nairobi, 00200, Kenya
  • Research Site
    Siaya, 40600, Kenya
  • Research Site
    Beirut, 11-0236, Lebanon
  • Research Site
    Tripoli, 961, Lebanon
  • Research Site
    Cape Town, 7700, South Africa
  • Research Site
    Soweto, 2013, South Africa
  • Research Site
    Barakaldo, 48903, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28009, Spain
  • Research Site
    Mbeya, 2410, Tanzania
  • Research Site
    Antalya, 7070, Turkey
  • Research Site
    Mersin, 33343, Turkey
  • Research Site
    Seyhan, 01130, Turkey
  • Research Site
    Kampala, 10005, Uganda
  • Research Site
    Masaka, 0000, Uganda
  • Research Site
    Cardiff, CF14 4XW, United Kingdom
  • Research Site
    Glasgow, G51 4TF, United Kingdom
  • Research Site
    London, E1 1BB, United Kingdom
  • Research Site
    London, SE1 7EH, United Kingdom
10

References and documents

Publications

  • Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Astrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 2022 Sep 29;140(13):1470-1481. doi: 10.1182/blood.2021014095. PubMed 35849650 ↗
  • Heeney MM, Abboud MR, Amilon C, Andersson M, Githanga J, Inusa B, Kanter J, Leonsson-Zachrisson M, Michelson AD, Berggren AR; HESTIA3 study investigators. Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemp Clin Trials. 2019 Oct;85:105835. doi: 10.1016/j.cct.2019.105835. Epub 2019 Aug 22. PubMed 31446143 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Aug 2020, 22 months.

Results were first posted in Apr 2021, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2018
First posted
Aug 6, 2018
StartActual
Sep 26, 2018
Primary completionActual
Aug 13, 2020
CompletionActual
Aug 13, 2020
Results first posted
Apr 9, 2021
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03615924
Lead sponsor
AstraZeneca
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Aug 6, 2018
Start date
Sep 26, 2018
Primary completion
Aug 13, 2020
Completion
Aug 13, 2020
Results posted
Apr 9, 2021
Last update
Apr 9, 2021

Study contacts

Anders Berggren, MD, PhD
study director · AstraZeneca
Matthew Heeney, MD
principal investigator · Harvard Medical School (HMS and HSDM)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion